NorthStar Medical Radioisotopes has appointed its executive Dave Wilson to a new position as part of a reorganization it says will boost availability of molybdenum-99 (Mo-99) in the U.S. and advance development of other radioisotopes.
Wilson will serve as vice president of the company's Advanced Radiopharmaceutical and Therapeutic Technologies business, with responsibilities that will include advancing the radioisotopes copper-67, actinium-225, and FibroScint (technetium-99m F4A), the last of which is partnered with Capella Imaging through commercial development.
In a statement, NorthStar said that the appointment is part of a broader reorganization that will also help expand the capacity and production of Mo-99. Wilson previously held the position of vice president, commercial operations, and has been with NorthStar for five years.
